Mitsubishi Tanabe Pharma America Presents New Results of RADICAVA® (edaravone) for People Living with ALS at the European Network to Cure ALS (ENCALS) Meeting 2024

Posted on by

Real-world analysis suggests 3.2-month survival benefit for individuals treated with RADICAVA and riluzole compared to those treated with only riluzole No new safety concerns in final results from long-term Phase 3 safety extension study in RADICAVA ORS® (edaravone) JERSEY CITY, N.J.,…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.